Next-Generation In Vitro Diagnostics (IVD) Market Report 2026 Market Outlook Supported By A Forecast 9.8% CAGR

The next-generation in vitro diagnostics (IVD) market is poised for substantial expansion as technological advancements and healthcare needs evolve. This sector is witnessing increasing attention due to its potential for improving diagnostic precision and enabling more personalized treatment approaches. Let's explore the market's expected growth, key players, emerging trends, and segment details to understand its future trajectory.

Market Size and Growth Outlook for the Next-Generation In Vitro Diagnostics Market
The next-generation in vitro diagnostics market is anticipated to experience significant growth, reaching a valuation of $188.69 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 9.8% during the forecast period. The surge is driven by multiple factors, including the rising demand for precision medicine, broader applications of genomic testing, increased usage of point-of-care diagnostics, accelerated healthcare digitization, and growing investments in diagnostic research and development. Key trends shaping the market include a shift towards personalized and companion diagnostics, rapid integration of decentralized and point-of-care testing, adoption of multiplex and high-throughput assays, heightened focus on early disease detection and screening, and the growth of non-invasive liquid biopsy methods.

Download a free sample of the Next-Generation In Vitro Diagnostics (IVD) market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25848&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Leading Companies Steering the Next-Generation In Vitro Diagnostics Market
Several influential players dominate the next-generation in vitro diagnostics landscape. Notable companies include F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Becton dic*kinson and Company, Agilent Technologies Inc, Illumina Inc, Sysmex Corporation, Bio Rad Laboratories Inc, Revvity Inc, Exact Sciences Corporation, QIAGEN NV, DiaSorin SpA, Singular Genomics Systems Inc, Guardant Health Inc, Pacific Biosciences of California Inc, Transasia Bio Medicals Ltd, J Mitra and Co Pvt Ltd, Roche Diagnostics International AG, Hologic Inc, Genetron Health Inc, Seegene Inc, BGI Genomics Co Ltd, and Oxford Nanopore Technologies plc.
In a notable development, February 2023 saw SD Biosensor Inc., a South Korean in-vitro diagnostics company, together with SJL Partners LLC, acquire Meridian Bioscience Inc. for $1.53 billion. This acquisition strengthens SD Biosensor's capabilities by incorporating Meridian's expertise in diagnostic products and essential materials used in immunological and molecular testing. Meridian Bioscience, based in the US, specializes in providing in vitro diagnostic enzymes across various applications.

Important Drivers Fueling Growth in the Next-Generation In Vitro Diagnostics Market
A key driver behind the market's expansion is the increasing demand for precision medicine, which requires more accurate and tailored diagnostic solutions. As healthcare moves toward personalized care, the need for advanced diagnostic tools that can detect diseases early and guide targeted therapies becomes crucial.
Additionally, the widespread adoption of point-of-care diagnostics is accelerating growth. These diagnostics provide rapid results outside traditional laboratory settings, improving accessibility and patient outcomes. This trend is complemented by the ongoing digitization of healthcare systems, which streamlines diagnostic workflows and enables better data management.

View the full Next-Generation In Vitro Diagnostics (IVD) market report:
https://www.thebusinessresearchcompany.com/report/next-generation-in-vitro-diagnostics-ivd-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Current Trends Shaping the Next-Generation In Vitro Diagnostics Industry
Strategic partnerships are becoming a cornerstone of innovation in the next-generation in vitro diagnostics market. Companies are collaborating with technology providers, research institutions, and healthcare organizations to advance diagnostic accuracy and widen access to cutting-edge testing solutions.
For example, in October 2024, UK-based Yourgene Health partnered with Colombia's Genetix to introduce the country's first local non-invasive prenatal testing (NIPT) service. This collaboration leverages Yourgene Health's CE-marked IONA Nx NIPT Workflow, offering a scalable and flexible diagnostic platform. This initiative provides expectant parents in Colombia with faster, more reliable, and cost-effective prenatal genetic screening options, marking a significant advancement in regional prenatal care.

Detailed Segment Analysis of the Next-Generation In Vitro Diagnostics Market
This market is segmented across various categories to capture its diverse technologies and applications:

1) By Product Type:
- Consumables
- Instruments
- Software

2) By Diagnostic Modality:
- Core Laboratory Diagnostics
- Point-Of-Care Testing
- Molecular Diagnostics

3) By Application:
- Oncology or Cancer
- Infectious Diseases
- Diabetes
- Cardiology
- Other Applications

4) By End-User:
- Hospitals and Clinics
- Diagnostic Laboratories
- Academic and Research Institutions
- Other End Users

Subcategories further break down these segments. Consumables include assay kits and reagents, specimen bags and tubes, and seals and caps. Instruments range from automated sample preparation systems to high-throughput molecular diagnostic analyzers, next-generation sequencing platforms, integrated diagnostic workstations, and advanced PCR instruments like digital PCR systems. Software offerings encompass laboratory information management systems, specimen tracking modules, and cloud-based tracking solutions.

Regional Overview and Market Expansion Outlook
Currently, North America holds the largest share in the next-generation in vitro diagnostics market. However, the Asia-Pacific region is expected to witness the fastest growth in the coming years. The market analysis covers major regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa, providing a broad view of global market dynamics and opportunities.

Our 2026 market reports now include enhanced strategic insights through:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.